Twist Bioscience Corporation
Twist Bioscience Corporation
Your view on TWST
Overview
What the company does, where it operates, and who runs it.
About Twist Bioscience Corporation
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Emily Marine Leproust
- Headquarters
- 681 Gateway Boulevard, South San Francisco, CA, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Emily Marine Leproust
- Headquarters
- 681 Gateway Boulevard, South San Francisco, CA, US
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip.
It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.
; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets.
Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Twist Bioscience Corporation, and the rating behind it. TWST last traded at $127.22; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Twist Bioscience Corporation. Starting points for Twist Bioscience Corporation: EPS -$2.19, beta 2.22 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Twist Bioscience Corporation. Twist Bioscience Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Twist Bioscience Corporation. Trailing twelve-month EPS for Twist Bioscience Corporation stands at -$2.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Twist Bioscience Corporation. Twist Bioscience Corporation has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Twist Bioscience Corporation valued side by side against its closest peers. Twist Bioscience Corporation is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Twist Bioscience Corporation, and how their positions are changing. At a $7.92B market value, institutional positions materially move Twist Bioscience Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Twist Bioscience Corporation executives and directors. Shares of Twist Bioscience Corporation have traded between $23.30 and $55.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Twist Bioscience Corporation. Twist Bioscience Corporation is a $7.92B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Twist Bioscience Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Twist Bioscience Corporation. Coverage tracks Twist Bioscience Corporation within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.